lestaurtinib has been researched along with pervanadate in 1 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (pervanadate) | Trials (pervanadate) | Recent Studies (post-2010) (pervanadate) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 367 | 1 | 29 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allebach, J; Brown, P; Chen, P; Kim, KT; Levis, M; Small, D | 1 |
1 other study(ies) available for lestaurtinib and pervanadate
| Article | Year |
|---|---|
FLT3/ITD mutation signaling includes suppression of SHP-1.
Topics: Acute Disease; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; fms-Like Tyrosine Kinase 3; Furans; Humans; Hydrolysis; Indoles; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mutation; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Vanadates | 2005 |